Bone Marrow Transplantation· 2026Q1
Azacitidine maintenance after allogeneic hematopoietic stem cell transplantation in high-risk AML: a single-center retrospective study
- 0citations
- Q1SCImago
- 2026year
Short summary
Post-transplant azacitidine maintenance in high-risk AML patients after allogeneic stem cell transplantation (allo-HSCT) did not improve overall survival (OS) or relapse-free survival (RFS) compared to no maintenance, with 2-year OS at 69% and RFS at 60% in the azacitidine group.
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Hematology
HematologyMedicine